Richard Friedenheim, MD
Pulmonary Disease · Abington, PANPI 1144238676
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $491,626 of the $627,448 with a category attached, or 78.4%. 27 manufacturers reported payments, led by Jazz Pharmaceuticals Inc. at 30.9% of the total. Among pulmonary disease clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 816 payments — averaging $768.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$194K
- Sanofi$193K
- Regeneron Healthcare Solutions, Inc.$121K
- Axsome Therapeutics, Inc.$58K
- Boehringer Ingelheim$17K
- Avadel CNS Pharmaceuticals, LLC$15K
- plus $29K from 21 others
Across 6 payments — averaging $616.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Actelion Pharmaceuticals, Ltd$4K
What the payments were for
- Consulting fees$37,4186%
- Speaking & faculty fees$491,62678%
- Travel & lodging$78,30512%
- Food & beverage$19,5503%
- Education$5490%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 251 | $193,832 |
| Sanofi | 127 | $193,063 |
| Regeneron Healthcare Solutions, Inc. | 140 | $121,002 |
| Axsome Therapeutics, Inc. | 73 | $58,179 |
| Boehringer Ingelheim | 27 | $16,847 |
| Avadel CNS Pharmaceuticals, LLC | 30 | $15,451 |
| GSK | 38 | $10,313 |
| Genentech USA, Inc. | 21 | $9,524 |
| Mylan Specialty L.p. | 17 | $5,086 |
| Sunovion Pharmaceuticals Inc. | 7 | $1,928 |
| Harmony Biosciences LLC | 23 | $823 |
| AstraZeneca(2 entities) | 13 | $225 |
| Inari Medical, Inc. | 1 | $209 |
| Insmed, Inc. | 6 | $138 |
| United Therapeutics Corporation | 6 | $138 |
| Inspire Medical Systems, Inc. | 6 | $133 |
| Merck | 5 | $111 |
| Philips North America LLC | 7 | $109 |
| Bayer | 4 | $73 |
| Amgen | 3 | $68 |
| Resmed Corp | 3 | $55 |
| Advanced Respiratory, Inc | 2 | $34 |
| Sanofi-aventis U.S. LLC | 1 | $29 |
| Actelion Pharmaceuticals US, Inc. | 2 | $26 |
| Verona Pharma, Inc. | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Circassia Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$346,538
- SUNOSI$144,467
- XYWAV$101,967
- LUMRYZ$15,029
- XOLAIR$9,249
- TRELEGY ELLIPTA$8,625
- Yupelri$4,760
- LONHALA MAGNAIR$1,820
- ANORO ELLIPTA$1,200
- OFEV$1,050
- SPIRIVA$1,005
- FLOWTRIEVER CATHETER, S$209
- CT THROMBECTOMY SYSTEM KIT$209
- XYREM$150
How this compares
$627,448 in reported general payments places this provider in the 95th percentile of 703 pulmonary disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 97 | $78,774 |
| Breo ElliptaFluticasone/Vilanterol | 90 | $37,286 |
| Spiriva RespimatTiotropium Bromide | 60 | $34,123 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 61 | $31,431 |
| SymbicortBudesonide/Formoterol Fumarate | 39 | $13,326 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $10,076 |
| Arnuity ElliptaFluticasone Furoate | 41 | $8,854 |
| Spiriva HandihalerTiotropium Bromide | 14 | $7,845 |
| EliquisApixaban | 11 | $6,616 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 31 | $5,575 |
| Mometasone Furoate | 66 | $3,694 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 116 | $3,220 |
| BreynaBudesonide/Formoterol Fumarate | 21 | $3,102 |
| Modafinil | 67 | $2,981 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 17 | $2,678 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $10,313 | $156,344289 claims |
| Boehringer IngelheimSpiriva Respimat | $16,847 | $34,12360 claims |
| AstraZenecaSymbicort, Breztri Aerosphere | $225 | $23,40255 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 703 pulmonary disease providers in Pennsylvania.
Other pulmonary disease in Abington
- Paul DorinskyAbington$154K
- Sandeep Bansaldu Bois$1.4M
- Alan KanouffAltoona$809K
- Gerard CrinerPhiladelphia$657K
- Kenneth LanderUpland$647K
- Thomas MeyerWynnewood$615K
- Surya BhattBethlehem$579K
- Tariq CheemaPittsburgh$549K
- Stephen KovacsErie$520K
- Michael ZlupkoAltoona$468K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.